AtaGenix Laboratories

Home - About Us - Updates Center

Updates Center

  • AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
  • AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.
  • A recent industry analysis forecasts the first commercial launch of a bispecific antibody–drug conjugate (BsADC) by 2029, marking a major milestone in multispecific biologics. With 100+ BsADC candidates in clinical development, including more than 60 from China, the field is expanding rapidly. Advances in linker–payload technologies, bispecific formats, and regulatory learning from earlier ADCs are accelerating progress. For developers, this trend highlights both opportunity and competition. AtaGenix supports BsADC innovation with expertise in bispecific design, conjugation strategies, and early-stage engineering—helping partners gain a competitive edge in next-generation oncology therapeutics.
  • The global antibody discovery market, valued at USD 1.9 billion in 2024, is projected to reach USD 3.3 billion by 2030, with a CAGR of 9.8%. Growth is fueled by expanding pipelines in monoclonal antibodies, rapid adoption of bispecifics, and increasing investment in antibody–drug conjugates (ADCs). Advances in single B-cell technologies, AI-driven design, and stable cell line development are accelerating discovery and reducing development risks. As demand rises for next-generation biologics, AtaGenix provides integrated discovery, screening, and engineering platforms to help researchers and partners achieve faster, cost-effective progress.
  • On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
  • On August 13, 2025, BioTAG from Israel visited AtaGenix’s Wuhan headquarters to discuss antibody drug development, protein engineering, and CRO services. The collaboration aims to advance precision medicine and biopharmaceutical innovation globally.
  • AtaGenix will participate in LAB International 2025, taking place in Thailand from September 3 to 5, 2025. Visit Booth 2S21 to explore our capabilities in antibody discovery, engineering, protein expression, and purification, as well as the abinScience portfolio of recombinant proteins and antibodies. Let’s connect and discuss potential collaborations.
Messages